China Pharma Holdings (CPHI) Non-Current Debt (2013 - 2025)

China Pharma Holdings has reported Non-Current Debt for 12 years, with the latest figure at $1.3 million in Q2 2025.

• For the quarter ending Q2 2025, Non-Current Debt fell 5.93% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2025 stood at $1.3 million (down 5.93% YoY), and the FY2024 full-year result was $1.4 million, down 1.47% from the prior year.
• Non-Current Debt for Q2 2025 stood at $1.3 million, down from $1.4 million in the prior quarter.
• The five-year high for Non-Current Debt was $1.5 million in Q3 2022, with the low at $325072.0 in Q2 2021.
• Historically, Non-Current Debt has averaged $1.2 million across 5 years, with a median of $1.4 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Debt plunged 59.75% — and 2022, when it jumped 92.5%.
• China Pharma Holdings' Non-Current Debt stood at $800000.0 in 2021, then jumped by 92.5% to $1.5 million in 2022, then fell by 8.32% to $1.4 million in 2023, then decreased by 1.47% to $1.4 million in 2024, then declined by 5.12% to $1.3 million in 2025.
• The last three Non-Current Debt figures came in at $1.3 million (Q2 2025), $1.4 million (Q1 2025), and $1.4 million (Q4 2024), per Business Quant data.